论文部分内容阅读
目的检测并分析长链非编码RNA CCAT2在肾癌中的表达水平及其表达与患者临床特征之间的关系。方法通过实时荧光定量PCR检测肾癌及癌旁正常组织、肾癌细胞系(ACHN、786-O)及人胚肾细胞系(293T)中长链非编码RNA CCAT2的表达水平,通过配对t检验比较配对组织间表达差异;列出四格表,通过Fisher确切概率法探究CCAT2表达水平与患者临床特征之间的关系。结果 32例肾癌组织中26例(81.25%)表达升高,CCAT2在肾癌组织中表达水平明显升高(P<0.01),正常组织中CCAT2相对表达量为1±0.205 85,肾癌组织中CCAT2相对表达量为12.817 12±0.551 67;CCAT2在293T细胞中表达水平明显低于786-O、ACHN细胞(P<0.01),293T细胞中CCAT2相对表达量为1±0.004 88,786-O细胞中CCAT2相对表达量为15.670 72±1.075 72,ACHN细胞中CCAT2相对表达量为36.504 44±8.990 78;CCAT2在临床分期、分级较高的肾癌组织中升高更明显(P<0.05)。未发现CCAT2表达水平和患者年龄、性别、肾癌组织类型之间的相关性(P>0.05)。结论肾癌组织中CCAT2表达升高,提示CCAT2与肾癌发生相关。
Objective To detect and analyze the expression of long-chain non-coding RNA CCAT2 in renal cell carcinoma and its relationship with the clinical features of patients. Methods Real-time fluorescent quantitative PCR was used to detect the expression of long-chain non-coding RNA CCAT2 in renal cell carcinoma and adjacent normal tissues, renal cell carcinoma cell line (ACHN, 786-O) and human embryonic kidney cell line (293T) Comparison of paired tissue expression differences; tabulated four tables to investigate the relationship between CCAT2 expression levels and clinical features by Fisher’s exact test. Results The expression of CCAT2 was significantly increased in 32 cases of renal cell carcinoma (81.25%), the expression of CCAT2 in renal cell carcinoma (P <0.01), the relative expression of CCAT2 in normal tissues was 1 ± 0.205 85, CCAT2 relative expression level of 12.817 12 ± 0.551 67; CCAT2 in 293T cells was significantly lower than 786-O, ACHN cells (P <0.01), CCT2 293T cells in the relative expression of 1 ± 0.004 88,786-O cells The relative expression level of CCAT2 was 15.670 72 ± 1.075 72, and the relative expression level of CCAT2 in ACHN cells was 36.504 44 ± 8.990 78. CCAT2 increased more significantly in the clinical stage and higher grade renal cell carcinoma (P <0.05). No correlation was found between CCAT2 expression level and patient’s age, sex and type of renal cell carcinoma (P> 0.05). Conclusion The expression of CCAT2 in renal cell carcinoma is elevated, suggesting that CCAT2 is associated with renal cell carcinoma.